NasdaqGS:NUVLBiotechs
Nuvalent ASCO 2026 Data Puts Neladalkib And Zidesamtinib In Focus
Nuvalent plans to present pivotal clinical trial data at the 2026 ASCO Annual Meeting.
The presentations include neladalkib data in ALK-positive NSCLC that supported a recent FDA NDA submission and an ongoing Phase 3 trial.
The company will also share the first clinical look at zidesamtinib in ROS1-positive solid tumors, including early response data.
Nuvalent (NasdaqGS:NUVL) is drawing attention ahead of ASCO 2026 as it prepares to showcase data that underpin a recent FDA NDA filing for...
